The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

Blood 2004 Apr 20;103(8):2879-91. Epub 2003 Nov 20.

Division of Hematology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA 94305-5821, USA.

Idiopathic hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL) comprise a spectrum of indolent to aggressive diseases characterized by unexplained, persistent hypereosinophilia. These disorders have eluded a unique molecular explanation, and therapy has primarily been oriented toward palliation of symptoms related to organ involvement. Recent reports indicate that HES and CEL are imatinib-responsive malignancies, with rapid and complete hematologic remissions observed at lower doses than used in chronic myelogenous leukemia (CML). These BCR-ABL-negative cases lack activating mutations or abnormal fusions involving other known target genes of imatinib, implicating a novel tyrosine kinase in their pathogenesis. A bedside-to-benchtop translational research effort led to the identification of a constitutively activated fusion tyrosine kinase on chromosome 4q12, derived from an interstitial deletion, that fuses the platelet-derived growth factor receptor-alpha gene (PDGFRA) to an uncharacterized human gene FIP1-like-1 (FIP1L1). However, not all HES and CEL patients respond to imatinib, suggesting disease heterogeneity. Furthermore, approximately 40% of responding patients lack the FIP1L1-PDGFRA fusion, suggesting genetic heterogeneity. This review examines the current state of knowledge of HES and CEL and the implications of the FIP1L1-PDGFRA discovery on their diagnosis, classification, and management.

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2003-06-1824DOI Listing
April 2004
8 Reads

Publication Analysis

Top Keywords

tyrosine kinase
12
chronic eosinophilic
8
eosinophilic leukemia
8
diagnosis classification
8
classification management
8
hypereosinophilic syndrome
8
syndrome chronic
8
fusion tyrosine
8
imatinib suggesting
4
leukemia cml
4
cml bcr-abl-negative
4
myelogenous leukemia
4
abnormal fusions
4
fip1l1 cel
4
chronic myelogenous
4
respond imatinib
4
activating mutations
4
patients respond
4
cel patients
4
doses chronic
4

References

(Supplied by CrossRef)

Similar Publications